Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The company traded as high as C$12.50 and last traded at C$12.50, with a volume of 1188 shares changing hands. The stock had previously closed at C$11.89.
Fennec Pharmaceuticals Stock Performance
The company has a market cap of C$233.34 million, a PE ratio of -204.97 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The business has a 50-day moving average of C$10.80 and a 200 day moving average of C$9.44.
Insider Activity at Fennec Pharmaceuticals
In related news, Director Rostislav Christov Raykov sold 10,000 shares of the company's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of C$11.71, for a total transaction of C$117,096.00. Also, Senior Officer Robert Christopher Andrade acquired 8,220 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The shares were purchased at an average price of C$6.99 per share, with a total value of C$57,433.14. Over the last 90 days, insiders sold 39,913 shares of company stock worth $402,086. 16.20% of the stock is owned by insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
